natgillin/translations-raw huggingface dataset:
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Mylan has been shown to have comparable quality and to be bioequivalent to Lyrica.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pregabalin Mylan võrreldav kvaliteet ja bioekvivalentsus ravimiga Lyrica.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Mylan Pharma has been shown to have comparable quality and to be bioequivalent to Lyrica.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pregabalin Mylan Pharma võrreldav kvaliteet ja bioekvivalentsus ravimiga Lyrica.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Sandoz GmbH has been shown to have comparable quality and to be bioequivalent to Lyrica.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Pregabalin Sandoz GmbH võrreldav kvaliteet ja bioekvivalentsus ravimiga Lyrica.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Sandoz has been shown to have comparable quality and to be bioequivalent to Lyrica.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Pregabalin Sandoze võrreldav kvaliteet ja bioekvivalentsus ravimiga Lyrica.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Zentiva has been shown to have comparable quality and to be bioequivalent to Lyrica.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pregabalin Zentiva võrreldav kvaliteet ja bioekvivalentsus ravimiga Lyrica.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Rasagiline Mylan has been shown to have comparable quality and to be bioequivalent to Azilect.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Rasagiline Mylan võrreldav kvaliteet ja bioekvivalentsus ravimiga Azilect.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Rivastigmine 3M Health Care Ltd has been shown to have comparable quality and to be bioequivalent to Exelon.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Rivastigmine 3M Health Care Ltd võrreldav kvaliteet ja bioekvivalentsus ravimiga Exelon.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Tadalafil Mylan has been shown to have comparable quality and to be bioequivalent to Cialis.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Tadalafil Mylan võrreldav kvaliteet ja bioekvivalentsus ravimiga Cialis.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Taxespira has been shown to be comparable to Taxotere.
Kasutamata ravimpreparaat või jäätmematerjal tuleb hävitada vastavalt kohalikele nõuetele.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Tolucombi has been shown to have comparable quality and to be bioequivalent to MicardisPlus.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Tolucombi võrdväärne kvaliteet ja bioekvivalentsus ravimiga MicardisPlus.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Voriconazole Accord has been shown to have comparable quality and to be bioequivalent to Vfend.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Voriconazole Accordi võrdväärne kvaliteet ja bioekvivalentsus ravimiga Vfend.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Voriconazole Hospira has been shown to be comparable to Vfend.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Voriconazole Hospira sarnane toime ravimiga Vfend.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Zoledronic Acid Accord has been shown to have comparable quality and to be comparable to Zometa.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Zoledronic Acid Accordi võrdväärne kvaliteet ja bioekvivalentsus ravimiga Zometa.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Zoledronic acid Teva Generics has been shown to be comparable to Aclasta.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Zoledronic acid Teva Generics võrreldavus Aclastaga.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Zonisamide Mylan has been shown to have comparable quality and to be bioequivalent to Zonegran.
Inimravimite komitee järeldas, et Euroopa Liidu nõuete kohaselt on tõendatud ravimi Zonisamide Mylan võrreldav kvaliteet ja bioekvivalentsus ravimiga Zonegran.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered that although the effectiveness of the medicine in promoting weight loss was limited, it was sufficient to be clinically significant, and mandatory re-assessment of treatment after 4 months should ensure that the medicine only continues to be used in those in whom the medicine provides adequate benefit.
Inimravimite komitee oli seisukohal, et kuigi ravimi efektiivsus kaalu langetamisel on piiratud, on see kliiniliselt piisavalt oluline ja ravi kohustuslik taashindamine 4 kuu järel peaks tagama, et ravimi kasutamist jätkavad ainult need, kellele ravim on piisavalt kasulik.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered that Odefsey is an alternative treatment option to Eviplera with similar effectiveness.
Inimravimite komitee leidis, et Odefsey on Eviplerale alternatiivne ravim, millel on samasugune efektiivsus.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered that the active ingredients are a well-known local anaesthetic combination, and the use of a local spray minimises the amount of active substance absorbed and hence the risk of side effects affecting the body as a whole.
Euroopa Ravimiameti inimravimite komitee järeldas, et toimeained on hästi tuntud lokaalanesteetikumide kombinatsioon ning paikse sprei kasutamine vähendab imendunud toimeaine hulka ja seega organismi tervikuna mõjutavate kõrvalnähtude ohtu.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered that the benefits of Truberzi are modest but there is an unmet need for treatments of irritable bowel syndrome with diarrhoea.
Ameti inimravimite komitee oli arvamusel, et Truberzi kasulikkus on vähene, kuid kõhulahtisusega soole ärritussündroomi ravivõimaluste vajadus on täitmata.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered that the combination of fenofibrate and simvastatin has been shown to be effective at improving blood fat levels.
Inimravimite komitee leidis, et fenofibraadi ja simvastatiini kombinatsioon on vere rasvasisalduse parandamisel efektiivne.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered that the use of lutetium (177Lu) for radiolabelling medicines was well documented in the scientific literature.
Inimravimite komitee oli seisukohal, et luteetsiumi(177Lu) kasutamine ravimite radiomärgistamiseks on teaduskirjanduses hästi dokumenteeritud.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered that the use of lutetium (177Lu) for radiolabelling medicines was well established and well documented in the scientific literature.
Inimravimite komitee oli seisukohal, et luteetsiumi(177Lu) kasutamine ravimite radiomärgistamiseks on hästi tõestatud meditsiiniline kasutus ja teaduskirjanduses hästi dokumenteeritud.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered the increase in progression free survival to be clinically significant although it noted that a benefit in overall survival had not yet been shown.
Inimravimite komitee oli seisukohal, et progressioonivaba elulemuse suurenemine oli kliiniliselt tähtis, kuigi märkis, et veel ei ole tõendatud kasulikkus üldisele elulemusele.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Abilify Maintena’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Abilify Maintena kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Adempas’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Adempase kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Anoro’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Anoro kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Aubagio’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Aubagio kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Blincyto’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Blincyto kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Bosulif’s benefits are greater than its risks in a sub-group of patients with an unmet medical need and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Bosulifi kasulikkus on suurem kui sellega kaasnevad riskid meditsiinilise erivajadusega patsientide alarühmas, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Brimica Genuair’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Brimica Genuairi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Briviact’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Briviacti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Cerdelga’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Cerdelga kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Cinqaero’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Cinqaero kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Cometriq’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Cometriqi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Corbilta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Corbilta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Cosentyx’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Cosentyxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Cotellic’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Cotellicu kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Cyramza’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Cyramza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Deltyba’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Deltyba kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Descovy’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Descovy kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Duaklir Genuair’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Duaklir Genuairi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Duavive’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Duavive kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Duloxetine Lilly’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Duloxetine Lilly kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Dutrebis’ benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Dutrebise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ebymect’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Ebymecti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Edistride’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Edistride kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Entresto’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Entresto kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Entyvio’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Entyvio kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Enzepi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Enzepi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Erivedge’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Erivedge kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Evotaz’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Evotazi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Feraccru’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Feraccru kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Fexeric’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Fexerici kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Flixabi has been shown to have a comparable quality, safety and effectiveness to Remicade.
Inimravimite komitee otsustas, et Flixabi kvaliteet, ohutus ja efektiivsus on võrreldavad Remicade vastavate näitajatega.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Fluenz Tetra’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Fluenz Tetra kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Galafold’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Galafoldi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Gardasil 9’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et vaktsiini Gardasil 9 kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Gazyvaro’s benefits are greater than its risks and recommended that it be approved for use in the European Union (EU).
Inimravimite komitee otsustas, et Gazyvaro kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Genvoya’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Genvoya kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Granupas’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Granupase kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Harvoni’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Harvoni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Hemangiol’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Hemangioli kasulikkus on suurem kui sellega kaasnevad riskid ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Hetlioz’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Hetliozi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Hexacima’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Hexacima kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Hexyon’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Hexyoni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Iblias’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Ibliase kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Iclusig’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Iclusigi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ikervis’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Ikervise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Imbruvica’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Imbruvica kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.